Right. It boils down to Lonza now. There have been CRLs related to mfg issues for other biotechs I have been involved in.
I am counting on Lonza's experience and expertise in coming through though.
C'mon Lonza!
example:
https://www.fiercepharma.com/regulatory/manufacturing-questions-lead-to-another-crl-for-allergan-migraine-drug
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection, page-31
-
- There are more pages in this discussion • 245 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |